Physician profile
Michael S Phillips
NPI 1154391431
$16,227.56
in general payments reported to CMS, 2019-2025
65 companies · $3,099 in 2025
The $3,099 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,641 · 2020: $1,333 · 2021: $1,870 · 2022: $1,974 · 2023: $3,103 · 2024: $3,208 · 2025: $3,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,396 · Education: $13.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,396.22 |
| Education | $13.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,623.05 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,506.93 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,259.67 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $1,169.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $893.76 | 2022-2025 | |
| Pfizer INC. | $796.99 | 2019-2025 | |
| Amgen INC. | $768.72 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $759.61 | 2019-2025 | Ofev, Jardiance, Synjardy |
| Abbvie INC. | $628.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $620.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Acadia Pharmaceuticals INC | $579.42 | 2023-2025 | Nuplazid |
| Merck Sharp & Dohme LLC | $524.57 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Astellas Pharma US INC | $382.67 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $380.80 | 2023-2025 | Gemtesa, Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.14 | 2019-2024 | Xifaxan |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.